1. PAST, PRESENT AND FUTURE
MarkPap Technology
PAST, PRESENT AND FUTURE
BioSciCon, 2007

2. BioSciCon, Inc.
BioSciCon is a women-owned small business company that has developed and has rights to manufacture, market and sale patented biomarker-based MarkPap® technology products intended for cytological early detection of cervical cancer/pre-cancer. MarkPap technology is more accurate, faster and less costly than current Pap test technologies.
December 9, 2018
Business Overview 2007

3. MarkPap® technology: Biomarker makes a difference
MarkPap biomarker is cytoplasmic expression of genetic changes in cervical cells during
transformation from normal to pre-malignant (dysplastic) and malignant, with or w/o HPV infection. When visualized with MarkPap test biomarker appears as a red pigment flagging only abnormal cells.
December 9, 2018
Business Overview 2007

4. MarkPap test applied in Pap test as a new ancillary method
Abnormal specimen, ASC-H.
Three small abnormal (red) cells
among several normal cells.
Screening magnification (left).
Diagnostic magnifications (right).
Abnormal cells cannot be missed!
December 9, 2018
Business Overview 2007

5. Biomarker is positive in cancer and HPV induced abnormal cells
MarkPap smear from a patient with invasive cervical carcinoma HPV positive.
Red biomarker is positive in all abnormal cells where micro-vacuolization and dysplastic features are present together
December 9, 2018
Business Overview 2007

6. MarkPap screening and HPV vaccines
Cervical cancer was the major killer of women with malignant diseases. Measures for prevention and control, such as mass screening with low-cost and accurate methods such as MarkPap, with added benefit of HPV vaccines, raise hopes for cervical cancer eradication in the years to come.
December 9, 2018
Business Overview 2007

7. CLINICAL TRIALS RESULTS
2,000 s/s
NEW
CTR-1 Pap
CTR-2 LBP
Advantage
Ancillary
CAP
Pap
ThP
CAP+PAP
MarkPap
D-Ac, Se, FN
Diagnostic Accuracy*
0.93
0.51
0.82
1.8:1:1.6
Sensitivity
0.88
0.8
1.7:1:1.5
False negative 4 18 17
1:5:4
December 9, 2018
Business Overview 2007

8. Intellectual Property Market protection
MarkPap is currently protected:
1. Parent patent US PTO # 6,143,512
Granted November 2000
2. Patent pending
3. International Application (PCT 2004)
4. Trademark MarkPap®
Continuing developments:
5. Digital MarkPap (TelePap)
6. MarkPap for home self-testing (HomePap)
December 9, 2018
Business Overview 2007

9. Competitive MarkPap® advantages on the market
Better accuracy for lower cost
Better productivity for less liability
Mass cervical cancer screening worldwide with HomePap and TelePap
Huge societal benefit saving women’s lives with enormous market and incredible potential for profit .
December 9, 2018
Business Overview 2007

10. Market Opportunity – WORLD 1.7 billion women at risk
Developing countries
1,400 M women at risk
100 M test per year
Outreach 6.5%
China
300 M women at risk
72 M test and growing
Outreach 24%
US & EU
250 M women at risk
95 M tests annually
3-5 B dollars market
Outreach: ~80% at 3 years
US/EU
250M
Risk
China
300M
Risk
Developing Countries
1.4 Billion Women at
Risk
December 9, 2018
Business Overview 2007

11. Returns to investors Negotiable terms for investment:
Percent of profit on sales of the product (royalty)
Percent interest in the MarkPap LLC (equity investment)
Interest on investment
BioSciCon offers all options to investors.
December 9, 2018
Business Overview 2007

12. MarkPap technology in the next decade
Towards this vision, we are developing a palette of products which are unique because they are based on the proprietary biomarker. They include new types of specimen collection (MarkPap Self), digital imaging for fast, reliable and low-cost diagnosis at distance (MarkPap Digital) and automation for specimen processing, reading and interpretation (MarkPap Auto). New products as MarkPap Cervical Cell Bank are envision to provide material for further basic research and new drug development
December 9, 2018
Business Overview 2007

13. BioSciCon in the next decade
BioSciCon ultimate goal is the HomeTelePap test for global cervical cancer screening, monitoring of the effects of HPV vaccination and saving thousands of women’s lives.
The business arm MarkPap LLC to manufacture, market, distribute and sale MarkPap technology products
Independent non-profit corporation to collect and organize past, present and future BioSciCon activities for the advancement of education and science on women’s health.
December 9, 2018
Business Overview 2007

14. Acknowledgement The National Institutes of Health
NIH SBIR Program (1R43CA , 1R43CA , 2R44CA )
NIH Commercialization Assistance Program
Larta Institute, San Francisco, CA
December 9, 2018
Business Overview 2007

15. BioSciCon, Inc. MarkPap, LLC Web site: www.bioscicon.com
14905 Forest Landing Circle
Rockville, MD 20850
Shady Grove Development Park,
Gaithersburg, MD 20877
Frederick Innovation Technology Center, Frederick, MD 21701
TeL:
Fax:
Web site:
December 9, 2018
Business Overview 2007